Previous Article | Next Article ![]()
Journal of Bacteriology, January 2003, p. 413-421, Vol. 185, No. 2
0021-9193/03/$08.00+0 DOI: 10.1128/JB.185.2.413-421.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111
Received 29 August 2002/ Accepted 28 October 2002
|
|
|---|
|
|
|---|
One putative transcriptional regulator identified by STM is RlrA (10), a homologue of RofA and Nra from S. pyogenes (6, 22). Through sequence analysis, rlrA has been shown to be one of seven genes in a pathogenicity islet of approximately 12 kb (Fig. 1) (10) that is not highly conserved in other S. pneumoniae strains (26). Of the six genes that are divergently transcribed from rlrA, three have homology to the LPXTG family of cell wall-anchored surface proteins (rrgA, rrgB, and rrgC). RrgA, RrgB, and RrgC have C-terminal sorting signals that are characteristic of LPXTG-containing proteins, except that the leucine of LPXTG is deviant in each protein. RrgB and RrgC have conservative changes to isoleucine and valine, respectively, whereas RrgA has a change to tyrosine. The C-terminal sorting signals predict that these proteins are covalently anchored to the cell wall by sortases, which are transpeptidases found in most gram-positive bacteria (15, 20). Interestingly, three of the four sortase homologues (srtB, srtC, and srtD) encoded in the TIGR4 genome lie within the rlrA pathogenicity islet; however, no proteins are known to be sorted by these sortases (Fig. 1) (10, 20, 26).
|
View larger version (7K): [in a new window] |
FIG. 1. The rlrA pathogenicity islet. The 12-kb locus includes a positive regulator, three surface proteins, and three sortase homologues. The four genes that are required for virulence in one or more animal models are in white (10).
|
On the basis of the homology of RlrA to other gram-positive transcriptional regulators, the organization of the islet, and the phenotypes of certain mutant strains in animal assays, we previously proposed a model of regulation in the rlrA pathogenicity islet in which RlrA positively regulates the transcription of each rlrA pathogenicity islet gene. In this report, we confirm this model by demonstrating that transcription of each gene in the islet is dependent upon RlrA. Furthermore, RlrA is shown to act at four different promoters within the islet at a consensus sequence that is found elsewhere in the S. pneumoniae chromosome, suggesting that although the rlrA pathogenicity islet may function autonomously at both the level of transcription and the protein secretion level, there may be additional targets of regulation in the TIGR4 chromosome.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Strains and plasmids used in this study
|
|
View this table: [in a new window] |
TABLE 2. Sequences of the primers used in this study
|
RPAs. Total RNA was isolated from 10 ml of exponential-phase S. pneumoniae with the Qiagen RNeasy kit in accordance with the manufacturer's (Qiagen) recommendations. Template DNA for the generation of riboprobes was PCR amplified with the primer sets RLRAF2/RLRAR7, RRGAF3/RRGAR3, RRGBF2/RRGBR1, RRGCF2/RRGCR2, SRTBF2/SRTBR1, SRTCF2/SRTCR2, SRTDF2/SRTDR2, SRTAF1/SRTAR1, and RPOBF3/RPOBR3. The resulting products were purified with a QIAquick PCR purification kit, subsequently cloned into pGEM-T (Promega), and confirmed by PCR with both an SP6 or T7 primer and a primer specific to the cloned insert. These plasmids (AC1279 to AC1286 and AC1293; Table 1) were used as templates for the generation of riboprobes as previously described (19). Synthesized probes were purified on a 4% denaturing polyacrylamide gel containing 7 M urea. RNase protection assays (RPAs) were carried out as described by the manufacturer with an RPAII kit (Ambion). The protected fragments were visualized by exposing each gel to a phosphorimaging screen (Kodak) and analyzed with a Storm 860 scanner and IQMac V1.2 imaging software. The relative amount of each protected fragment in each assay was normalized to the amount of rpoB protected RNA in each lane.
Northern blotting. Northern blots were performed with the NorthernMax analysis kit (Ambion) exactly as described by the manufacturer with 5 µg of total RNA. Riboprobes were synthesized as described above. Total RNA was separated on a 1% formaldehyde agarose gel by electrophoresis and subsequently transferred to Hybond-N+ nitrocellulose membranes. Membranes were then probed with 106 cpm of gel-purified riboprobe per ml of hybridization buffer and washed as recommended by the manufacturer (Ambion). Processed blots were exposed to a phosphorimaging screen (Kodak) and analyzed as described above.
Primer extension and DNA sequencing.
Primer extension reactions were carried out with the avian myeloblastosis virus reverse transcriptase primer extension system (Promega). RNA was isolated from AC1278 as described above. A primer corresponding to the 5' end of each coding sequence was end labeled with [
-32P]ATP with T4 polynucleotide kinase for 10 min at 37°C. The primers used were RLRAPE2, RRGAP2, RRGBPE, RRGCPE, SRTBPB, SRTCPE, and SRTDPE (Table 1). End-labeled primers were annealed to total RNA extracted from AC1278 by incubation at 58°C for 20 min, followed by cooling to room temperature for 10 min. Avian myeloblastosis virus extension mixture was added to each annealed primer, and cDNA synthesis was carried out at 42°C for 30 min.
Preliminary experiments were carried out with primers that were designed to be within 50 to 100 bp of the translation start site for each respective gene. In the case of rrgA and srtB, the resulting cDNA products were too large to be resolved by electrophoresis and only a single product was observed, indicating that no additional transcriptional start sites were present between the larger product and the translation start site (data not shown). Thus, two new primers (RRGAP2 and SRTBPB) were designed in the 5' untranslated region of the RNA, resulting in products of approximately 150 bp.
DNA fragments predicted to contain promoter regions in the islet were PCR amplified from AC353 with the primer sets RLRA2/RRGA2, RRGB2/RRGBR1, RRGC2/RRGBF2, SRTBP1/SRTBP2, and SRTCD1/SRTCD2. PCR products were purified with the Stratagene PCR purification kit in accordance with the protocol provided (Stratagene), and purified products were subsequently cloned into pGEM-T (Promega) to generate plasmids AC1287, AC1288, AC1289, AC1290, and AC1291, respectively. DNA sequencing of rlrA pathogenicity islet promoter regions was performed with the Sequenase 2.0 DNA sequencing kit in accordance with the manufacturer's (USB) specifications. Briefly, strains AC1287, AC1288, AC1289, AC1290, and AC1291 were grown in 4 ml of Luria-Bertani broth and plasmid DNA was purified with a QIAGEN Plasmid Mini Kit (Qiagen). Plasmid DNA was resuspended in 100 µl of TE (10 mM Tris [pH 8.0], 1 mM EDTA) and subsequently denatured by the addition of 25 µl of 1 N NaOH-10 mM EDTA and incubation at 37°C for 30 min. Single-stranded DNA was ethanol precipitated by the addition of 1/10 volume of 3 M sodium acetate (pH 5.2) and 2 volumes of 100% ethanol. Precipitated DNA was resuspended in 1x Sequenase reaction buffer, and 60 pmol of the appropriate primer was annealed by incubation at 37°C for 30 min. Sequencing reactions were performed by the addition of a Sequenase 2.0 reaction mixture containing [
-35S]dATP and incubation at room temperature for 5 min. Next, 3.5 µl of each reaction mixture was added to 2.5 µl of each dideoxynucleotide at 37°C and the termination reaction mixture was incubated for 5 min, at which time the reaction was stopped by the addition of stop solution.
Primer extension products and sequencing reactions were denatured for 10 min at 80°C prior to electrophoresis on a 5% polyacrylamide-7 M urea sequencing gel (National Diagnostics). Gels were run at 45 W, dried with a Bio-Rad 853 gel drying apparatus, and analyzed as described above.
RlrA-His6 purification. The predicted coding sequence of RlrA was PCR amplified from AC353 with primers RLRAC1 and RLRAC2, subcloned into pGEM-T, and liberated by digestion with NcoI and BglII. The liberated fragment was ligated into similarly digested pQE60 to create AC1292. The resulting strain containing the coding sequence for RlrA with a C-terminal His6 tag was grown in 2 ml of Luria-Bertani broth containing ampicillin to an optical density at 600 nm of 0.5, and expression of RlrA was induced by the addition of isopropyl-ß-D-thiogalactopyranoside (IPTG) to 1 mM for 2 h. Proper expression of RlrA-His6 was assessed by separation of induced and uninduced cell culture extracts by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and subsequently by Western blotting with anti-His6 antibody (Roche) in accordance with the ECL Western blotting protocol (Amersham Pharmacia Biotech).
For the purification of RlrA-His6, 2 liters of AC1292 was grown as described above and induced with IPTG for 2 h. RlrA-His6 was subsequently purified on an Ni2+-nitrilotriacetic acid agarose column in accordance with the manufacturer's (Qiagen) protocols under native conditions. Briefly, induced cell cultures were lysed by sonication for five cycles of 30 s with 15-s rests between cycles. The cellular debris was removed by centrifugation, and protein in the supernatant was bound to Ni2+-nitrilotriacetic acid agarose beads for 1 h at 4°C. Bound protein was washed two times with wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0) and subsequently eluted with 2 ml of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0) in 0.5-ml fractions. Fractions containing RlrA-His6 were identified by Coomassie-stained gels and Western blotting with anti-His6 antibody (Roche). RlrA-His6-containing fractions were combined and concentrated with Centricon centrifugation filters (Amicon) to a final concentration of 800 nM.
Gel mobility shift assays of the rrgA-rlrA promoter region.
Overlapping DNA fragments of the rrgA-rlrA intergenic region were amplified by PCR with the primer set REGF1-AP3, IIR1-AP5, AP4-AP6, or IIR1-AP4 (AP7) and used in gel mobility shift assays with RlrA-His6. In each experiment, 60 pmol of a selected primer was end labeled with T4 polynucleotide kinase (New England Biolabs) and [
-32P]ATP (6,000 Ci/mmol, 150 mCi/ml) for 30 min at 37°C. Labeled primers were ethanol precipitated twice with ammonium acetate, resuspended in 10 µl of distilled H2O, and used in PCRs with pAC1287 as the template. Amplified products were separated on a 4% polyacrylamide gel, gel purified, and eluted overnight in gel mobility shift assay elution buffer (0.5 mM ammonium acetate, 10 mM magnesium acetate, 1 mM EDTA, 0.1% SDS) at 37°C. Gel mobility shift assay binding reactions were carried out with 5,000 cpm of each probe with increasing concentrations of RlrA-His6 at 30°C for 15 min in gel mobility shift assay binding buffer (20 mM Tris [pH 8.0], 50 mM KCl, 2 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 0.05% Nonidet P-40, 5% glycerol) supplemented with 1 µg of poly(dI) · poly(dC)-poly(dI) · poly(dC) and bovine serum albumin as nonspecific inhibitors. For the supershift experiments, binding reaction mixtures were prepared as described above, chilled on ice, and incubated with 0.5 µg of anti-His6 antibody (Roche) for 30 min on ice. Reaction mixtures were subsequently separated on 5% nondenaturing polyacrylamide gel at approximately 10 V cm-1(Protogel; National Diagnostics) and visualized as described above.
DNase I footprinting. DNase I footprinting experiments were carried out with the gel mobility shift protocol with 2 x 104 cpm of each probe. Following protein binding, the concentrations of MgCl2 and CaCl2 were adjusted to 5 and 10 mM, respectively, and each reaction mixture was incubated with DNase I (0.5 to 2 U) for 1 min at room temperature. Reactions were stopped by the addition of stop solution (200 mM NaCl, 30 mM EDTA, 1% SDS), and the digested products were extracted with an equal volume of phenol and chloroform and subsequently ethanol precipitated. Precipitated DNA was resuspended in loading buffer (98% formamide, 10 mM EDTA, 0.1% bromophenol blue, 0.1% xylene cyanol) and separated on a 5% polyacrylamide-7 M urea sequencing gel (National Diagnostics). Sequencing reactions of the footprinted region were performed as described above with primers specific to the region.
Determination of RlrA consensus binding sites.
A consensus RlrA binding site was determined by PRETTY (Genetics Computer Group software package) with the four RlrA binding sites determined by DNase I footprinting. The resulting consensus sequence was used to query the complete TIGR4 genomic sequence with FINDPATTERNS (Genetics Computer Group software package). The resulting sequences were analyzed to determine if the sequences were present in regions likely to contain S. pneumoniae promoters. Intergenic regions were examined for potential promoter sequences with the Neural Network Promoter Prediction program at the Berkeley Drosophila Genome Project (http://www.fruitfly.org/seq_tools/promoter.html), and the resulting output was visually examined for S. pneumoniae
70 consensus -10 binding sites. Consensus sequences located within 300 bp of a putative translational start site and within 70 bp of putative +1 transcriptional start sites were considered as possible sites of RlrA binding and regulation.
|
|
|---|
![]() View larger version (77K): [in a new window] |
FIG. 2. RPAs were performed to analyze the steady-state mRNA levels of each gene in the rlrA pathogenicity islet in both the wild-type (wt; AC353) and rlrA mutant (AC1213) strain backgrounds. (A) Riboprobes to each gene in the islet, as well as to rpoB, were generated and hybridized to 10 µg of total S. pneumoniae RNA from either the wild-type or the mutant strain. Lanes U and D contained undigested riboprobes or riboprobes digested by RNase in the absence of S. pneumoniae RNA. In each case, the experimental probe for the given gene in the upper part of the panel and the control rpoB probe in the lower part of the panel are from the same gel. (B) Riboprobes to srtA and rpoB were hybridized to the same samples in panel A and presented in the same manner. (C) A riboprobe that differentially recognizes the two rlrA transcripts in AC1278 was used to determine if RlrA is autoregulatory. The larger fragment in each lane represents the mRNA from the native rlrA pathogenicity islet promoter. Lanes marked with a plus sign are RNA samples that were harvested from cells grown in the presence of maltose.
|
RlrA is autoregulatory. In S. pyogenes, RofA positively regulates its own expression (5). To investigate the possibility that RlrA functions in a similar manner, a merodiploid strain that overexpressed rlrA from an inducible promoter was constructed (AC1278). This strain contained two copies of rlrA; one present in the rlrA pathogenicity islet and a second copy integrated into the maltose utilization operon downstream of malM (24). In the latter case, expression of rlrA was under the control of the malM promoter (PmalM), and thus, its expression was inducible by the addition of maltose to the growth medium (1). In addition, the Shine-Dalgarno site of rpoB was engineered into the rlrA construct upstream of the rlrA initiation codon to ensure maximal efficiency of RlrA translation from the maltose utilization locus.
To determine if overexpression of rlrA (from PmalM) activated transcription from the native rlrA promoter (PrlrA), RPAs were performed with a single riboprobe specific for rlrA that differentiates between the two transcripts. The riboprobe was completely complementary to the PrlrA transcript, as it overlapped the coding sequence of rlrA and the 5' untranslated mRNA, resulting in a 409-bp protected band. Alternatively, the rlrA riboprobe was only partially complementary to the PmalM transcript and resulted in a smaller protected fragment since the sequence upstream of the rlrA coding sequence in this locus is different from that in the rlrA pathogenicity islet. Because of these differences, the two different-size protected messages detected with the same riboprobe were used to assess the quantity of steady-state mRNA from either of these promoters.
As shown in Fig. 2C, an increase in the amount of rlrA mRNA initiated from PrlrA was observed in strain AC1278 compared to AC353 when each strain was grown in the absence of maltose. The increase observed in the absence of inducer compared to AC353 was due to the fact that AC1278 contained two copies of rlrA and transcription from PmalM is not completely repressed during growth in THY. A sixfold increase in expression from PrlrA was observed in strain AC1278 compared to AC353 when each strain was grown in the presence of maltose. No increase in rlrA expression was observed when AC353 was grown in maltose compared to the same strain grown in THY, confirming that the increase in rlrA expression in AC1278 is not due simply to growth in the presence of maltose. Together, these data show that RlrA is autoregulatory in addition to activating the expression of the other six genes in the rlrA pathogenicity islet.
Transcription in the rlrA pathogenicity islet initiates at four different promoters.
The finding that AC1213 (rlrA::magellan2) exhibited decreased levels of steady-state mRNA of different genes in the islet by differing levels led to the hypothesis that RlrA acts at numerous sites within the locus. To identify sites of transcription initiation and thus sites of potential RlrA activity, a primer specific to each gene in the locus was synthesized and used for primer extension analysis. By this method, transcription initiation sites upstream of rlrA, rrgA, rrgB, and srtB were identified (Fig. 3). By analysis of the sequences upstream of the predicted transcriptional start sites,
70 consensus -10 and -35 sequences were identified for rlrA and an extended -10 sequence (25) was found for rrgA and rrgB; however, no such sequences were found for the srtB promoter (Fig. 3A and B). These results support the model in which there are multiple promoters within the islet and thus multiple sites at which RlrA acts.
![]() View larger version (91K): [in a new window] |
FIG. 3. (A) Transcriptional start sites of promoters upstream of rlrA, rrgA, rrgB, and srtB were mapped by primer extension analysis. The arrows indicate primer extension products. (B) Graphical depiction of the four rlrA pathogenicity islet promoters. A rightward arrow indicates the +1 start site. When present, -10 and -35 70 consensus sequences and predicted Shine-Dalgarno (SD) sequences are underlined and in bold.
|
![]() View larger version (40K): [in a new window] |
FIG. 4. Northern blot of rlrA pathogenicity islet mRNAs. Riboprobes to selected genes were synthesized and used to hybridize to total RNA recovered from AC1278 (lane 1) or AC1213 (lane 2) grown under maltose-inducing conditions. (A) Northern blots probed with rrgB and rrgC riboprobes. (B) Northern blots probed with srtB, srtC, and srtD riboprobes.
|
RlrA-His6 acts at the rrgA and rlrA promoters. To determine if RlrA directly acts at one or more of the promoters in the rlrA pathogenicity islet, a C-terminally His6-tagged version of RlrA was purified from E. coli. To test if RlrA-His6 was able to bind to rlrA pathogenicity islet promoter sequences, the noncoding sequence between rrgA and rlrA was amplified by PCR with the primer set REGF1/IIR1 and an end-labeled REGF1 primer (Fig. 5A). The resulting fragment was incubated with purified RlrA-His6 and separated on a nondenaturing polyacrylamide gel. In this gel mobility shift assay, RlrA-His6 retarded the mobility of the probe evinced by the presence of multiple species that migrated more slowly on the gel than the probe alone (data not shown). This shows that RlrA-His6 retains DNA binding activity and indicates that it binds to multiple sequences between rrgA and rlrA.
![]() View larger version (37K): [in a new window] |
FIG. 5. Gel mobility shift analysis with RlrA-His6. (A) The four 32P-labeled probes that span the rrgA-rlrA intergenic region and were used in gel mobility shift analyses are depicted. The sizes of the PCR fragments were as follows: AP1, 522 bp; AP3, 250 bp; AP4, 139 bp; AP5, 163 bp; AP7, 290 bp. (B) Gel mobility shift analysis of AP4 and AP5. 32P-labeled probes were incubated with increasing concentrations of RlrA-His6. The protein concentrations used were as follows: lanes 1 and 8, 0 nM; lanes 2 and 9, 0.25 nM; lanes 3 and 10, 1 nM; lanes 4 and 11, 4 nM; lanes 5 and 12, 16.4 nM; lanes 6 and 13, 33 nM; lanes 7 and 14, 66 nM. The arrows indicate shifted species. (C) Supershift of RlrA-His6 complexes by the addition of anti-His6 antibody to the binding reaction mixture. The protein concentrations used were as follows: lanes 1 and 4, no protein; lanes 2 and 5, 16.4 nM RlrA-His6; lanes 3 and 6, 16.4 nM RlrA-His6 and 0.5 µg of anti-His6 antibody.
|
To confirm that the retarded mobility of the probe was due to the binding of RlrA-His6 and not a contaminating species in the purified protein preparation, anti-His6 antibody was added at the conclusion of the binding reaction to supershift RlrA-His6-specific species. Figure 5C shows that incubation of RlrA-His6-bound complexes with anti-His6 antibody resulted in the appearance of a third complex migrating higher on the gel. This tertiary complex demonstrates that it is indeed RlrA-His6 that is bound to the AP4 and AP5 probes. Together, these data suggest that RlrA-His6 specifically binds to three distinct sites between the rrgA and rlrA transcription initiation sites, resulting in activation of transcription from both the rrgA and rlrA promoters.
Determination of RlrA-His6 binding sites. DNase I footprinting was used to precisely map the sites of RlrA binding in the rrgA and rlrA promoter regions. RlrA-His6 was incubated with the AP7 fragment as described above, and the resulting bound complexes were subjected to DNase I digestion. Consistent with the findings of the gel mobility shift experiments, RlrA-His6 protected three discrete regions of DNA (Fig. 6A). Two of these regions were present within 80 bp of the rlrA transcriptional start site (-28 to -43 and -47 to -76), and a third, larger region was present within 80 bp of the rrgA transcriptional start site (-36 to -76; Fig. 6A and B), which we believe constitutes two binding sites that are similar in arrangement to the rlrA binding sites. When the complementary strand of DNA was end labeled and used in the same assay, the same binding patterns were identified for both the rlrA and rrgA promoters (data not shown). Alignment of the protected regions revealed that RlrA binds to AT-rich regions close to the RNA polymerase binding site and transcriptional start site of each gene (Fig. 6B). The four binding sites identified were aligned, and a 13-bp RlrA consensus binding site was determined, as shown in Fig. 6C. The consensus sequence was used to query the TIGR4 genome sequence for additional possible RlrA binding sites. This search resulted in the identification of 153 sequences, 29 of which are present in putative promoter regions and 14 of which lie within 70 bp of the putative +1 transcriptional start site. These data suggest that RlrA may regulate additional genes outside of the rlrA pathogenicity islet.
![]() View larger version (45K): [in a new window] |
FIG. 6. (A) DNase I footprinting analysis of the rrgA-rlrA promoter regions. The 32P-labeled AP7 probe was incubated with increasing amounts of RlrA-His6 and subsequently treated with DNase I. The protein concentration used were as follows: lane 1, 0 nM; lane 2, 0.5 nM; lane 3, 2.05 nM; lane 4, 8.2 nM; lane 5, 32.8 nM. The amounts of DNase I used were as follows: lanes 1 and 2, 0.5 U; lane 3, 1 U; lanes 4 and 5, 2 U. Brackets indicate areas protected by RlrA-His6. (B) The rlrA and rrgA promoter regions. The nucleotide sequence of each promoter is shown, and a hooked arrow denotes the +1 transcription initiation site. RlrA binding sites are singly underlined, and consensus binding sites are doubly underlined. (C) Alignment of the four consensus RlrA binding sites within the rlrA and rrgA promoter regions. Nucleotides that are identical to those in the consensus sequence are in bold, and the consensus sequence is in bold and boxed. In both cases, the sequence labeled number 1 is the consensus site closest to the transcriptional start site for that gene.
|
|
|
|---|
RlrA exhibits amino acid sequence similarity to a number of S. pyogenes transcriptional regulators, including RofA and Nra, a positive and a negative regulator, respectively. Both RofA and Nra regulate their own expression, as well as a number of different surface proteins that interact with eukaryotic extracellular matrices and thus are important to the pathogenesis of S. pyogenes (6, 8, 22). In each case, the gene divergently transcribed from the regulator is one target of regulation.
To determine if RlrA is a regulator of neighboring genes and of its own transcription, we used RPAs to measure the steady-state levels of transcription of each gene in the rlrA pathogenicity islet. We found that RlrA positively regulates the transcription of each gene (Fig. 2). The decrease in each message in the rlrA mutant strain was compared to that in the wild-type strain. On the basis of this analysis, rlrA-dependent expression fell into three categories: expression of the rrgA gene was only slightly affected, srtBCD expression was decreased to an intermediate level, and rrgBC expression was drastically reduced. The role of RlrA in its own expression was analyzed with a merodiploid strain that expressed rlrA from the malM promoter, allowing inducible expression in the presence of maltose. Analysis of this strain revealed that RlrA positively regulates its own transcription.
The different levels of expression of each gene in the islet suggest that RlrA regulates multiple promoters within the islet. Indeed, by using primer extension analysis, we mapped transcripts initiating upstream of rlrA, rrgA, rrgB, and srtB. A consensus
70 -35 and -10 binding site was found upstream of rlrA, indicating that rlrA is expressed constitutively but may also be subject to positive autoregulation by increased RlrA levels under unknown conditions. In contrast, in three cases, rrgA, rrgB, and srtB,
70 consensus -35 boxes could not be identified upstream of the transcriptional start sites; however, extended -10 sequences for rrgA and rrgB were identified. Previous studies of other S. pneumoniae promoters have shown that -35 consensus sequences cannot always be found within DNA fragments with known promoter activity (25). It is conceivable that genes such as those in the rlrA pathogenicity islet are transcribed by alternative
factors, such as ComX, which regulates a subset of competence-induced genes (14). Comparison of the sequences upstream of the srtB promoter to the consensus comX box did not reveal an obvious binding site (21), indicating that this promoter is ComX independent and may be transcribed with an unknown sigma factor that is aided by RlrA binding. Alternatively, RlrA may enhance transcription by stimulating binding of
70 RNA polymerase holoenzyme to the poor -35 elements in the rrgA, rrgB, and srtB promoters.
The identification of multiple promoters that are regulated by RlrA indicated that RlrA must bind multiple sites within the islet to regulate gene expression. This was indeed shown to be the case by gel mobility shift analyses and DNase I footprinting. In these experiments, RlrA was demonstrated to directly bind to four sites within the rlrA-rrgA intergenic region: two sites upstream of rlrA and two sites upstream of rrgA. In each case, there is a smaller RlrA binding site near the transcriptional start site and a larger binding site at a more distal location. A 13-bp consensus sequence in present in all four sites, and we propose that it is this sequence that is bound directly by RlrA. It is curious that the smaller site in each promoter overlaps the -35 sequence in each promoter, which is expected to be bound by RNA polymerase. As mentioned above, a consensus
70 -35 promoter sequence could be identified in the rlrA promoter but not in the rrgA, rrgB, or srtB promoter. Thus, these data suggest that RlrA may compete with
70 for the smaller binding site in the rlrA promoter, possibly when RlrA is expressed at high levels, resulting in repression of RlrA expression.
An interesting aspect of the biology of the rlrA pathogenicity islet is that it is not conserved among all pneumococcal serotypes (11, 26). Therefore, this islet may require a means of autonomous regulation, as we demonstrate here. On the other hand, it may seem unlikely that RlrA would regulate chromosomal genes outside the islet. However, we identified a number of putative targets of rlrA regulation outside the islet and scattered throughout the genome. It will be interesting to analyze these loci to see if they are indeed regulated by RlrA.
The srtBCD genes represent three of the four sortase homologues in the TIGR4 S. pneumoniae genome. The presence of multiple sortase homologues is a common occurrence in gram-positive bacteria genomes. The role of sortases in the anchoring of surface proteins important for the pathogenicity of various organisms is well documented. To our knowledge, however, prior to the finding that srtBCD are regulated by RlrA, only one other sortase has been shown to be regulated at the transcriptional level (17). The finding reported here that three of the four pneumococcal sortases are coordinately regulated by a single regulator suggests that RlrA may indirectly regulate the expression of numerous cell wall-anchored proteins by controlling sortase expression from a single promoter. It remains formally possible that the multiple sortase homologues in the rlrA pathogenicity islet do not have substrates that lie outside of the islet. In this case, the role of SrtB, SrtC, and SrtD may be to specifically anchor one or more of the Rrg proteins to the cell wall. This would add a second, posttranslational level of autogenous regulation to the rlrA pathogenicity islet.
This work was supported by Pew Scholars Award P0168SC to A.C. and D.L.H. and by Welcome Trust Research Training Fellowship 061036 to C.J.H.
|
|
|---|

-based shuttle mutagenesis strategy in Streptococcus pyogenes. Mol. Microbiol. 11:671-684.[CrossRef][Medline]
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»